Abstract CYP2D6 is a critical pharmacogenetic target, and polymorphisms in the gene region are commonly used to infer enzyme activity score and predict resulting metabolizer phenotype: poor, intermediate, extensive/normal, or ultrarapid which can be useful in determining cause and/or manner of death in some autopsies. Current genotyping approaches are incapable of identifying novel and/or rare variants, so CYP2D6 star allele definitions are limited to polymorphisms known a priori. While useful for most predictions, recent studies using massively parallel sequencing data have identified additional polymorphisms in CYP2D6 that are predicted to alter enzyme function but are not considered in current star allele nomenclature. The 1000 Genomes Project data were used to produce full-gene haplotypes, describe their distribution in super-populations, and predict enzyme activity scores.
Introduction
The cytochrome p450 family 2 subfamily D polypeptide 6 (CYP2D6) enzyme is part of a large family of CYPs responsible for a substantial portion of hepatic phase I metabolism of foreign compounds and endogenous toxins [1, 2] . The enzyme has been implicated in drug metabolism variation of clinical and medico-legal relevance [3, 4] . Current methods of pharmacogene analyses employ targeted approaches, such as genome wide association studies of candidate single nucleotide polymorphisms (SNPs) and SNP-targeted massively parallel sequencing (MPS) of known a priori SNPs and/or insertion/deletion polymorphisms (INDELs) [5] . The CYP2D6 allele nomenclature, in the Human Cytochrome P450 Allele Nomenclature Database (HCYPAND) [6] , identifies and defines polymorphisms that confer each CYP2D6 star (*) allele (the collection of polymorphisms within the gene region). CYP2D6 * allele genotypes (g), or diplotypes, commonly provide inferences of metabolizer phenotype (MP; poor (gPM), intermediate (gIM), normal/extensive (gNM/ gEM), or ultrarapid (gUM) CYP2D6 activity) [1, 2, 6, 7] . It has been demonstrated both clinically and medico-legally that CYP2D6 information can result in increased prescription Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00414-017-1709-0) contains supplementary material, which is available to authorized users. efficacy and inference of idiosyncratic effect during accident reconstruction [4, [8] [9] [10] [11] . In fact, Koren et al. [4] and Koski et al. [8, 9] have used targeted genotyping of CYP2D6 to make inferences regarding the cause and/or manner of death in a series of medico-legal cases. However, targeted genotyping approaches inherently are incapable of revealing novel polymorphisms that may further refine CYP2D6 * alleles and the associated metabolic differences observed in clinical cases and medico-legal investigations. MPS of the full gene region has the potential to reveal additional polymorphisms and refine predictions of CYP2D6 activity.
Wendt et al. [12] characterized 418 polymorphisms in CYP2D6 exons, introns, 3′ and 5′ untranslated regions, and promoter region in the 1000 Genomes Project dataset. Ninetyseven (23.2%) of the polymorphisms are currently used by HCYPAND to classify some of the < 150 CYP2D6 * alleles observed to date. The remaining 321 polymorphisms have a wide range of allele frequencies in the African (AFR), Admixed American (AMR), East Asian (EAS), European (EUR), and South Asian (SAS) super-populations. Most notable are those polymorphisms predicted to damage, or most likely damage, CYP2D6 function. Ignoring these loci when determining CYP2D6 * alleles may lead to inaccurate predictions of enzyme function and incorrect conclusions for drug therapy or potential cause and/or manner of death investigations. The HCYPAND database has established inclusion criteria for newly observed CYP alleles [13] which put more emphasis on enzyme-altering polymorphisms for the sake of providing minimalist nomenclature. However, in medicolegal autopsy cases where incident reconstruction and cause and/or manner of death may be inferred from toxicology and genetic data [4, 8, 9] , a more comprehensive and inclusive nomenclature may be necessary. Herein, all typed loci from the 1000 Genomes Project data were used to generate and characterize full-gene CYP2D6 haplotypes. These data indicate that the phenotypic impact of some previously defined CYP2D6 * alleles may have been mischaracterized due to damaging polymorphisms occurring elsewhere in the gene relative to a HCYPAND causal SNP or INDEL. Mischaracterizations based on targeted genotyping and traditional * allele nomenclature may have clinical and medicolegal consequences, as a fraction of 1000 Genomes Project samples may be inaccurately placed into MP categories.
Materials and methods
Polymorphisms in the CYP2D6 gene region (introns, exons, 5′ and 3′ untranslated regions (UTRs), and promoter) were downloaded from phase 3 of the 1000 Genomes Project [14, 15] and analyzed individually in 5 super-and 26 subpopulations (Table S1 ) according to Wendt et al. 2017 [12] . 1000 Genomes Project CYP2D6 haplotypes containing reportedly phased polymorphisms [16] were aligned to the hg38 and hg19 reference genomes and the M33388 GenBank accession reference sequence (Table S2) for ease of community comparison [17] https://www.ncbi.nlm.nih. gov/nuccore/M33388?report=GenBank, https://www.ncbi. nlm.nih.gov/nucleotide/45024927 [18] . CYP2D6 full-gene haplotypes were named relative to the reverse DNA strand of three reference sequences with the following nomenclature format: reference sequence (genome name or GenBank Accession Number)-HCYPAND CYP2D6 * allele designation-polymorphism rs number, if known, followed by the base at that position. Note that if an rs number is not provided for a specific location, the nucleotide position and base change, relative to the indicated reference, are provided. For example, haplotype 1 is named M33388-CYP2D6: 5157insCCCACCCCTT, hg19-CYP2D6: rs28439297A; rs28680494G; rs1080983G; rs1080985C; rs28735595A; rs28624811C; rs28633410G; rs1808995G; rs1080996C; rs74644586C; rs76312385T; rs75276289G; rs28695233A; rs1081000A; rs28371699G; rs28371701C; rs28371702T; rs1058164G; rs16947C; rs28371730G; rs1135840G; rs116390392G; rs71184866insACA; rs35028622T; rs34386013T, and hg38-CYP2D6: none, relative to the M33388, hg19, and hg38 reference genomes, respectively.
Full-gene CYP2D6 haplotypes and diplotypes for 2504 individuals in five super-and 26 sub-populations were created using excel-based workbooks. Private mutations (those polymorphisms observed once in the 1000 Genomes dataset), except those considered clinically relevant by HCYPAND and those predicted by Wendt et al. 2017 [12] to damage, or most likely damage, the resulting protein, were removed from haplotype formation to simplify downstream analyses. 1000 Genomes Project haplotypes were named according to the same convention described above. Genetic Data Analysis [19] was used to determine haplotype and diplotype frequencies, observed (H o ) and expected (H e ) heterozygosities, pairwise genetic distances, and perform tests for detection of departures from Hardy-Weinberg Equilibrium (HWE). TreeView Version 1.6.6 Build 7601 [20, 21] and RStudio® [22] were used to create phylogenetic trees and multidimensional scaling (MDS) plots, respectively. Network analyses were performed using Population Analysis with Reticulate Trees (PopART) [23] . For comparison to HCYPAND CYP2D6 * alleles, full-gene haplotypes lacking amino acid changes and damaging intronic sequences are considered derivatives of CYP2D6*1 and full-gene haplotypes conferring R296C (or C296R for hg19-based haplotypes) and S486T (or T486S for hg19-based haplotypes), but no other amino acid changes or damaging intronic polymorphisms were considered derivatives of CYP2D6*2.
Activity scores were assigned to each allele (i.e., 0, 0.5, 1, or 2) and individual (i.e., 0, 0.5, 1, 1.5, 2, or 3) in two ways: (1) Full-gene haplotypes were assigned a most similar HCYPAND-recognized allele which was then assigned an activity score based on Gaedigk et al. [24] without considering the impact of additional polymorphisms not recognized by HCYPAND [6] . (2) Considering all polymorphisms, a bestand worst-case activity score were assigned to each full-gene haplotype. For example, haplotype 33 (M33388-CYP2D6: 310 T; 843G; 1067G; 5157insCCCACCCCTT) received an activity score of 1 based on the absence of HCYPAND causal polymorphisms only (resembling a normally active * allele). The presence of non-HCYPAND intronic polymorphism rs78854695, 1067G, damages splicing [12] , but its specific impact on CYP2D6 has not been confirmed empirically. So haplotype 33 was assigned best-and worst-case activity scores of 0.5 and 0, respectively.
Results
Histograms of SIFT [25] [26] [27] [28] [29] [30] , PolyPhen-v2 [25, 31, 32] , and PROVEAN [33] [34] [35] scores from Wendt et al. [12] for HCYPAND-recognized and non-HCYPAND polymorphisms ( Fig. 1) indicate that 29, 20, and 30 polymorphisms, respectively, from the 1000 Genomes Project dataset for CYP2D6 are predicted to negatively impact protein function. After removal of 138 private mutations, except those considered causal by HCYPAND and those considered damaging or most likely damaging based on Wendt et al. [12] , 446 unique fullgene haplotype string sequences were observed (Table S2) . Full-gene CYP2D6 haplotypes 11, 3, and 1 are identical to reference sequences M33388, hg19, and hg38, respectively. A majority of haplotypes were observed once in the global population, so the average global frequency of full-gene CYP2D6 haplotypes was quite low (0.00224 ± 0.0115 with a range of 0.165 (haplotype 1) to 0.000200 (haplotypes 205 through 446)). Haplotypes 1 through 18, had global frequencies ≥ 1%, with an average frequency of 0.0394 ± 0.0438 (Table 1 and Fig. 2 ). The average super-population frequencies for haplotypes 1 through 18 were 0.0348 ± 0.0382 in AFR, 0.0508 ± 0.0832 in AMR, 0.0110 ± 0.0169 in EAS, 0.0539 ± 0.0559 in EUR, and 0.0638 ± 0.102 in SAS.
One haplotype observed in this study was consistent with HCYPAND CYP2D6 * allele reference list (CYP2D6*1A [6], M33388-CYP2D6: None, hg19-CYP2D6: rs28439297A; rs28680494G; rs1080983G; rs1080985C; rs28735595A; rs28624811C; rs28633410G; rs10808995G; rs1080996C; rs74644586C; rs76312385T; rs75276289G; rs28695233A; rs1081000A; rs28371699G; rs28371701C; rs28371702T; rs1058164G; rs16947C; rs28371730G; rs1135840G; rs116390392G; rs71184866insACA; rs35028622T; rs34386013T; rs536156813delCCCACCCCTT, hg38-CYP2D6: rs536156813delCCCACCCCTT). Though not specifically reported in the HCYPAND CYP2D6 * allele table, 407 (91.3%) haplotypes could be associated with at least one * allele based on the presence of defining amino acid changes and causal polymorphisms; however, 38 (i.e., 8.52%) of them could not be associated. These 38 haplotypes were observed 125/5008 times (2.50%) in the 1000 Genomes Project and contain combinations of functionally relevant polymorphisms [6] . Figure 3 and Figure S1 represent the variant composition of haplotypes 1 through 18 and all 446 haplotypes, respectively. The average number of polymorphisms per haplotype was 15 ± 10, 20 ± 10, and 14 ± 10 as designated by comparison with the M33388, hg19, and hg38 reference sequences, respectively. The majority of each haplotype is functionally irrelevant polymorphic sites; however, 326, 328, and 326 haplotypes harbor a damaging, or most likely damaging, variant relative to the M33388, hg19, and hg38 reference genomes, respectively.
Network analysis was performed to determine the relatedness of two sets of haplotypes: (1) haplotypes having ≥ 1% global haplotype frequency (haplotypes 1-18; Fig. 4 ), and (2) haplotypes observed more than once in the entire 1000 Genomes Project dataset (haplotypes 1-204; Figure S2 ). In Fig. 4 and Figure S2 , the haplotypes with relatively low global frequencies appear to be derived from the major haplotypes (1, 2, and 3). All major haplotypes except 15 and 17 were observed in the AFR super-population, though the frequency is relatively low due to the AFR population having the widest haplotype spread ( Figure S2 ). Haplotype 9 is exclusive, and haplotypes 5, 6, 9, 13, and 18 are almost exclusive, to the AFR super-population. The clustering of rare haplotypes suggests that these may be specific to one super-population, such as AFR (minor haplotypes stemming from haplotypes 5, 6, 8, and 9) or EAS (minor haplotypes stemming from haplotypes 2, 15, and 17).
There were 961 unique diplotypes observed across 2504 individuals. The average global diplotype frequency was 0.00104 ± 0.00336. Ten diplotypes had global frequencies ≥ 1%, with an average global frequency of 0.0275 ± 0.0177 (Table 1 ). The average diplotype frequency in the AFR, AMR, EAS, EUR, and SAS super-populations was 0.00253 ± 0.00277, 0.00587 ± 0.0133, 0.00658 ± 0.0227, 0.00466 ± 0.00688, and 0.00568 ± 0.0142, respectively (Fig. 5) . The average global H o and H e of CYP2D6 were 0.820 ± 0.0898 and 0.861 ± 0.0923, respectively. Before Bonferroni correction (p < 0.05), CYP2D6 deviated from HWE expectations in three super-populations (AFR, AMR, and EUR) and nine sub-populations (ASW, GWD, LWK, MSL, YRI, CLM, CDX, CHS, and GBR) (Fig. 6 ). After Bonferroni correction (p < 0.00161), CYP2D6 deviated from HWE expectations in the AFR super-population and the ASW and LWK sub-populations.
Activity scores were assigned to each individual using the functional consequence of the most closely related HCYPAND-recognized * allele to each full-gene haplotype. Two hundred eighty-two individuals harbor full-gene haplotypes that, by HCYPAND nomenclature, should confer normal activity enzymes (activity score = 1), but full-gene data reveal additional causal polymorphisms that were predicted to damage enzyme function (Fig. 7) . Twenty-two of these individuals (21 AFR and 1 AMR) have diplotypes where two full-gene haplotypes produce conflicting activity scores relative to the HCYPAND approach. The average individual activity scores were 1.40 ± 0.644, 1.36 ± 0.638, and 1.30 ± 0.675 based on HCYPAND guidelines, full-gene best-(Student's t test, p < 0.05 relative to the HCYPAND approach), and full-gene worst-case (Student's t test, p < 0.001 relative to the HCYPAND approach) haplotype activity score designation. Haplotype 8 (M33388-CYP2D6: -2060G; -2053T; -1594C; -1418A; -1408A; -1235G; -740T; 176A; 310T; 744delC; 746G; 843G; 1659A; 1661C; 2123T; 2215G; 2292A; 2850T; 3183A; 4180C; 4719G; 4864C; 5157insCCCACCCCTT) is responsible for the majority of conflicting MP predictions (111 AFR and 2 AMR individuals). By HCYPAND nomenclature, this haplotype would be assigned an activity score of 0.5 based on similarity to CYP2D6*29 [40] ; however, full-gene haplotype data reveal the presence of non-HCYPAND INDEL rs267608275delC (744delC). Due to lack of empirical observation of the influence rs267608275delC has on CYP2D6 function, worst-and best-case activity scores of 0 and 0.5, respectively, were assigned for full-gene haplotypes, indicating that rs267608275delC may or may not further decrease CYP2D6 function. This significant decrease in average activity score suggests that by current CYP2D6 * allele and activity score designation,~11% of the individuals in this dataset may be wrongly considered gNM-F, gNM-S, or gIM when they likely belong in the gNM-S, gIM, and gPM categories, respectively.
MDS plots and unrooted phylogenetic trees (Fig. 8 ) of super-populations show distant separation of the AFR and EAS populations while EUR, AMR, and SAS cluster relatively close together. Considering sub-populations, those belonging to the AFR and EAS super-populations cluster together according to super-population affiliation. Subpopulations belonging to the AMR, EUR, and SAS superpopulations have considerable overlap with one another.
Discussion
Full-gene CYP2D6 haplotypes may be able to refine MP predictions, ultimately identifying more gIM and gPM individuals than the HCYPAND haplotype nomenclature. The analyses presented here may be limited by the relative low depth of sequence coverage per sample within the 1000 Genomes Project database, small sample size for each sub population, and the precision of variant effect prediction algorithms. These factors impact detection of rare variants that may contribute to CYP2D6 function. In fact, the splice defects defining three * alleles (CYP2D6*4, CYP2D6*11, and CYP2D6*41) were not identified by the software analyses performed in Wendt et al., and the 843G SNP was incorrectly identified as damaging [6] , emphasizing the importance of using variant effect predictors with caution and employing multiple prediction algorithms to identify single nucleotide variants of interest [41] . Additional rare variants will continue to be discovered for PM, IM, and/or UM individuals and/or isolated populations such as Finns or Ashkenazi Jews. While potentially contributing significantly to phenotype, variant effect prediction is not possible; however, the analysis herein may allow for some prediction of phenotype using a number of previously unexploited polymorphisms [42] [43] [44] [45] . Additional research is needed (e.g., functional enzyme studies, targeted mutagenesis, and/or quantitative trait analyses) to empirically characterize the phenotype generated from rare polymorphisms, combinations of rare/deleterious polymorphisms in the same haplotype, [25, 31, 32] , and Protein Variant Effect Analyzer (PROVEAN) (c) [33] [34] [35] scores from Wendt et al. [12] for The Human CYP Allele Nomenclature Database recognized polymorphisms (black bars) and polymorphisms not considered by the database (red bars). Arrows indicate the threshold applied to scores from each algorithm to predict the damaging or benign effect a polymorphism has on protein function; scores < 0.05, > 0.5, < − 2.5 for SIFT, PolyPhenv2, and PROVEAN, respectively, may impact protein function Tolerant (SIFT) [25] [26] [27] [28] [29] [30] , Polymorphism Phenotyping v2 (PolyPhen-v2) [25, 31, 32] , Protein Variant Effect Analyzer (PROVEAN) [33] [34] [35] , and Human Splicing Finder [39] combinations of deleterious polymorphisms in different genes that may influence one another, and their distributions in underrepresented populations. Copy number variation (CNV) of some CYP2D6 * alleles and CYP2D7 pseudogene conversion do occur in some individuals, namely UMs, and may influence the HWE and LD results [46] . It is likely that some 1000 Genomes Project individuals from the AFR super-population carry CNVs based on deviations from HWE expectations [46] , but the project does not explore CNV in detail due to limitations of short-read sequencing [47, 48] . The data presented herein have been analyzed as though only two copies of CYP2D6 are present in each individual, so unless an individual contains the SNP rs1135823G>T (1617G>T), the UM phenotype was not identified. A number of unique haplotypes have been identified that may be true haplotype observations but may also be attributed to duplication of two common haplotypes and/or CYP2D7 pseudogene conversions [49, 50] . This phenomenon is particularly true for African populations which exhibit relatively frequent gene duplications (up to 30%) [51, 52] . The development of continuous read single-molecule DNA sequencing strategies, such as nanopore technology [53] , may help reduce ambiguity in sequencing regions with a high degree of structural variation.
Unique haplotypes have been identified from the full-gene region of CYP2D6, including introns, exons, 5′ and 3′ UTRs, and the promoter region. While comprehensively assessing the gene itself, there are a number of distant regulatory elements that may impact enzyme function. Wang et al. [54] identified long-range haplotypes that include polymorphisms within enhancer regions that may refine these haplotype definitions. However, inclusion of such regulatory elements in CYP2D6-based MP predictions may need to be explored further due to potential regulation of other enzymes, potentially confounding MP prediction. Additionally, private mutations not predicted to damage the resulting protein have been removed (note that those considered for HCYPAND-recognized * alleles have been included) from this analysis; however, if incorporated, may produce finer granularity of haplotype definition but likely would not alter activity score unless empirically shown to alter enzyme function.
Full-gene CYP2D6 data have provided additional resolution to the MP compared to predictions used to date, possibly resolving some medico-legal autopsy negative cases. Although empirical data are required to confirm their enzyme activity, approximately 11% of the healthy individuals in this study may be wrongly identified as NMs according to traditional CYP2D6 genotyping and activity score predictions of MP. Clinically, these individuals likely would be classified as IM or PM and be treated accordingly. Enhanced predictive capabilities of MP may be made with comprehensive CYP2D6 diplotype information and/ or incorporation of a longer read sequencing platform into the CYP2D6 interrogation workflow.
The case described by Koren et al. [4] of an application of CYP2D6 genotyping to assist in a medico-legal investigation is a classic example of ultrarapid metabolism of codeine to morphine. In such cases, the medicaments were delivered as a pro-drug (inactive) that must be metabolized in order to deliver the intended effect (e.g., codeine or tamoxifen) [1, 2] . Given the prevalence of UM in various populations and the current use of these drugs, it is anticipated that similar cases will occur and molecular autopsies may shed light on the cause and/or manner of death. At the opposite end of the metabolizer phenotype spectrum are PMs and IMs. If considering codeine to morphine metabolism, CYP2D6 genotyping post-mortem may not be informative. However, many antidepressants (e.g., nortriptyline) are active upon administration and depend on CYP2D6 to deactivate the drug. PMs and IMs, based on their CYP2D6 variants, may experience adverse reactions to antidepressants which include, but are not limited to, delayed propagation of myocardium depolarization leading to cardiac arrhythmia, myocardial infarction, and death [10] . In the context of the data presented in this study,~11% of individuals may be incorrectly classified as NMs or IMs as their full-gene haplotype data indicate one category lower (i.e., NM by targeted approach is an IM by full-gene approach; IM by targeted approach is a PM by full-gene approach). As such, understanding CYP2D6 haplotype information of all metabolizer phenotypes can be quite relevant to the medicolegal community.
